argenex (NASDAQ:ARGX) Trading 6.3% Higher After Strong Earnings

argenex SE (NASDAQ:ARGX) rose 6.3% during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $904.98 and last traded at $905.12. 200,109 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 351,695 shares. The stock had previously closed at $851.72.

The company reported $7.32 EPS for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 70.27%. The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ARGX shares. Bank of America boosted their price target on argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Oppenheimer raised their price objective on argenex from $1,014.00 to $1,037.00 and gave the company an “outperform” rating in a research note on Friday. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Weiss Ratings downgraded argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Finally, Citigroup raised their price target on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,050.50.

Institutional Investors Weigh In On argenex

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sound Income Strategies LLC purchased a new position in argenex during the fourth quarter worth $28,000. Whipplewood Advisors LLC acquired a new stake in shares of argenex during the first quarter valued at $28,000. Eastern Bank purchased a new stake in argenex during the 2nd quarter worth about $32,000. Sunbelt Securities Inc. acquired a new position in argenex in the 3rd quarter valued at about $36,000. Finally, Axiom Investment Management LLC acquired a new position in argenex in the 1st quarter valued at about $50,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

The company has a market capitalization of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.14 and a beta of 0.45. The stock’s fifty day simple moving average is $868.28 and its 200-day simple moving average is $815.12.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.